Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Adsorbed Tetanus Vaccine (TTVA) in Adults
NCT06123663Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Dec 2023
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Tetanus Vaccine (Adsorbed) in Tetanus (2 arms), sponsored by CanSino Biologics Inc. Primary endpoint: Incidence of adverse reactions. Started Dec 2023; status: completed.
02
Drugs
Tetanus Vaccine (Adsorbed)
03
Conditions
Tetanus
Beyond the preview
Go deeper on NCT06123663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06123663.